Yeah no idea but that brings us back to the fact their 42 month OS is based on just 17 patients despite having data on 242 patients. And only 8 month rPFS on the 30 patients TLX actually trailed themselves. Hard to claim TLX591 is definitely better than pluvicto or CU6's based on that surely?(doens't mean it's not, just not enough information for mine), also I think makes TLX's claim of PSA reduction not being an indicator of OS somewhat questionable?
CU6 Price at posting:
$5.77 Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)